MIFH
BMRN icon

Migdal Insurance & Financial Holdings’s BioMarin Pharmaceuticals BMRN Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-31
Closed -$3K – 612
2021
Q4 		$3K Sell
31
-241
-89% -$19.9K ﹤0.01% 660
2021
Q3 		$21K Buy
+272
New +$21.5K ﹤0.01% 543

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Migdal Insurance & Financial Holdings's BMRN Position: Q1 2022 in Review

Migdal Insurance & Financial Holdings sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 31 shares — an estimated $3K sold.

Migdal Insurance & Financial Holdings first reported a position in BMRN in Q3 2021 and held it in 2 quarters. The position peaked at $21K in Q3 2021. 561 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

  • Migdal Insurance & Financial Holdings reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 31 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $3K.
  • Migdal Insurance & Financial Holdings first reported a position in BioMarin Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's BioMarin Pharmaceuticals position peaked at $21K in Q3 2021.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2022, filed 2 May 2022.